NEWS & COMMENTS

PROHOST    FILTER

Eye  On

GENENTECH (DNA): This firm’s financial results for the third quarter of 2006 are nothing but superior and “Wow” is our reaction, regardless of other comments that focus on future bad times, which are non-existent.  Total product sales increased by 34% and sales growth of all products increased without exception. While the firm’s revenues, earnings and product sales exceeded the most optimistic analysts projection, Lucentis extremely strong sales have been the big surprise. This is the mere reality. Whatever happens to the stock in the short term, this firm is undervalued and we believe that the stock will follow the staggering numbers and reach our target (See Prohost N-Letters and E-Letters.)  

READ MORE: Genentech Announces Third Quarter 2006 Results

ARIAD (ARIA) has been working hard at the time when investors decided to snub it while snubbing the whole sector. The firm, though, had no bad news and its drugs are based on validated pathway and were made possible through its technologies. One of these technologies and its fruits are highlighted today as the firm announced a non-exclusive, royalty-bearing license agreement to its proprietary ARGENT™ cell-signaling regulation technology with Bellicum Pharmaceuticals, Inc. to develop and commercialize new cancer therapies. ARIAD will have an equity stake in Bellicum and will receive additional payments based on certain development, regulatory and commercial milestones achieved by the company. Products in this partnership will use ARIAD's small-molecule dimerizer drug, AP1903, which already has successfully completed a Phase 1 clinical trial.

READ MORE: ARIAD Grants Commercial License to Its Patented ARGENT(TM) Cell-Signaling Regulation Technology for Development of New Cancer Therapies

ALNYLAM (ALNY): RNAi therapeutics are becoming more visible and the firms that specialize in this technology and other RNA technologies are also becoming more visible. (See Prohost N-Letters and E-Letters): One of the specialized group, Alnylam, announced that it has initiated a Phase I human clinical trial of an inhaled formulation of ALN-RSV01 in the U.S. to evaluate its safety, tolerability, and pharmacokinetics in healthy adult volunteers for the treatment of  respiratory syncytial virus (RSV) infection.

READ MORE: Alnylam Initiates Phase I Clinical Study of Inhaled Formulation of ALN-RSV01, an RNAi Therapeutic for the Treatment of Respiratory Syncytial Virus (RSV) Infection

Prohost is independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-cap and growth securities is highly speculative and carries a high degree of risk. It is possible that an investor can lose all of his/her investment in this type of companies that are profiled. The information that Prohost relies on is either through the profiled company, news services, research reports, interviews, or other outside sources that Prohost believes are reliable. Prohost makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure of the profiled companies and accepts no responsibilities for inaccuracies or misleading content in any material supplied by those clients. There can be no assurance that future events relating to the profiled company will occur as anticipated. The information contained herein is provided as an information service only. Past performance of featured companies does not guarantee the future success of any currently featured or profiled company. We encourage our readers to invest carefully and read the investor information provided by the Securities and Exchange Commission ("SEC") and/or the National Association of Securities Dealers ("NASD"). We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at: http://www.sec.gov/consumer/cyberfr.htm